4D Medical Shares Fall Despite Winning Australian TGA Approval
Synopsis
4D Medical received Australian TGA approval for its CT:VQ lung imaging software, enabling immediate commercialisation. Despite the milestone, shares dropped 10.7% as the company also confirmed plans to seek Medicare reimbursement.
Key Highlights
- 4D Medical got TGA approval for its CT:VQ imaging software in a breakthrough known to be the first of its kind around the world.
- The approval paves the way for immediate commercialisation throughout Australia.
- The company intends to apply for reimbursement under the Medicare Benefits Schedule.
4D Medical shares fell in afternoon trade even though the respiratory imaging company overcame its final regulatory hurdle to gain. Australian Therapeutic Goods Administration (TGA) has approved the CT:VQ imaging software of respiratory imaging company 4D Medical, enabling the company to commercially launch the product in Australia.
The stock fell 10.7% to $4.08 at 1:26pm AEST. Australia follows the USA, European Union, UK, Canada and New Zealand where regulatory approval of CT: VQ has already been granted.
Commercial Rollout
Approval supports 4D Medical’s milestone to firmly establish CT:VQ as the global standard for functional lung assessment, the company said. Australia has one of the highest densities of CT scanners globally, more than 74 per million people, holding second place.
4D Medical also announced it will be seeking reimbursement for the CT: VQ platform under the Medicare Benefits Schedule. Using this technology, a standard chest CT scan can now retrieve detailed regional lung ventilation data without the need for chemical injection or radiotracers.
Chief Executive Officer Andreas Fouras said that with TGA approval secured and reimbursement, 2026 highlights a pivotal period for the international expansion of 4D Medical's respiratory imaging technology.
Source: Capital Briefs
Follow Inspirepreneur Magazine for daily global business news.
At Inspirepreneurs Magazine, covering entrepreneurship, business failures, and the human stories behind the world's most ambitious founders. She writes at the intersection of strategy and storytelling.
